Latest Market Reactions News

Environmental Clean Technologies Limited (ECT) has had its trading suspension lifted following news of a potential material acquisition and capital raising, signaling renewed investor interest.

Supply Network Limited confirms a fully franked dividend of AUD 0.38 per share for FY2025, with shares under its Dividend Reinvestment Plan priced at AUD 33.53 each, reflecting a 2.5% discount.

Viva Energy Group Limited has updated its dividend announcement, confirming a fully franked interim dividend and setting the Dividend Reinvestment Plan price at a 1.5% discount.

TMK Energy Limited’s trading suspension on the ASX has been lifted as the company lodges its Half Yearly Report, reopening its shares to market activity from 16 September 2025.

TMK Energy Limited’s securities have been suspended from ASX trading due to a missed periodic report deadline, raising questions about the company’s regulatory adherence and market outlook.

Evolution Mining announces a robust 55.65% participation in its Dividend Reinvestment Plan, issuing over 16.6 million new shares at a discounted price of $8.73. The final dividend payment is set for early October alongside reiterated production guidance for FY2026.

DroneShield Limited has responded to ASX scrutiny over its disclosure of losing a $45.9 million Systems Integration Partner contract for Project LAND 156, denying the information was material to investors.

The Takeovers Panel has declined to intervene in the Elanor Commercial Property Fund's takeover bid by LDR Assets, following resolution of disclosure concerns.

333D Limited has responded to ASX inquiries following a sharp spike in its share price and trading volume, denying any undisclosed information but pointing to a recent Bitcoin strategy update as a possible catalyst.

Trading in Jindalee Lithium Limited shares has resumed following the company’s announcement of a potential merger, signaling a pivotal moment for the lithium miner.

Latitude 66 Limited has responded to an ASX price query concerning unusual trading activity, confirming no undisclosed material information exists and referencing prior announcements about a joint venture sale and recent assay results.

Pathkey.AI’s TrialKey platform has demonstrated a 73% alignment with actual biotech trial outcomes, showing an average hypothetical share price gain of 76%, underscoring AI’s growing role in clinical trial prediction and biotech investing.